European Journal of Cancer, Supplement : Impact Factor & More
eISSN: 1878-1217pISSN: 1359-6349
Open AccessShare this on:
Key Metrics
CiteScore 
1.2
SNIP
0.2
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
European Journal of Cancer, Supplement Journal Specifications
Indexed in the following public directories
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Elsevier |
| Language | English |
| Article Processing Charges | USD 3000 |
| Publication Time | 9 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | European Organisation for Research and Treatment of Cancer (EORTC); European Association for Cancer Research (EACR); European CanCer Organisation (ECCO); European Society of Mastology (EUSOMA) |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in European Journal of Cancer, Supplement ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in European Journal of Cancer, Supplement
Title page
- 1 Mar 2026
- European Journal of Cancer Supplements
Isocitrate dehydrogenase mutations as potential tumour agnostic targets☆
- 1 Mar 2026
- EJC Supplements
Disclaimer
- 1 Mar 2026
- European Journal of Cancer Supplements
Clinical advancement in the management of mutant isocitrate dehydrogenase (IDH) cancers☆
- 1 Mar 2026
- EJC Supplements
Table of contents
- 1 Mar 2026
- European Journal of Cancer Supplements
Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
- 1 Nov 2021
- EJC Supplements
Title page
- 1 Mar 2026
- European Journal of Cancer Supplements
Isocitrate dehydrogenase mutations as potential tumour agnostic targets☆
- 1 Mar 2026
- EJC Supplements
Disclaimer
- 1 Mar 2026
- European Journal of Cancer Supplements
Clinical advancement in the management of mutant isocitrate dehydrogenase (IDH) cancers☆
- 1 Mar 2026
- EJC Supplements
Table of contents
- 1 Mar 2026
- European Journal of Cancer Supplements
Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
- 1 Nov 2021
- EJC Supplements
FAQs on European Journal of Cancer, Supplement
How many articles did European Journal of Cancer, Supplement publish last year? 
What is the eISSN & pISSN for European Journal of Cancer, Supplement?
What is Citescore for European Journal of Cancer, Supplement?
What is SNIP score for European Journal of Cancer, Supplement?
Who is the publisher of European Journal of Cancer, Supplement?
